GT201000099A - Productos quimioterapéuticos cristalinos - Google Patents
Productos quimioterapéuticos cristalinosInfo
- Publication number
- GT201000099A GT201000099A GT201000099A GT201000099A GT201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A
- Authority
- GT
- Guatemala
- Prior art keywords
- crystal
- chemotherapeutic products
- chemotherapeutic
- products
- methylpenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A LA FORMA CRISTALINA 2 DE N-[4-(3-AMINO-1H-INDAZOL-4-IL) FENIL]-N´- (2-FLUORO -5-METILFENIL)UREA(ABT-869) QUE PERTENECE A UNA FAMILIA DE PROTEÍNA TIROSINA QUINASA (PTK) QUE CATALIZAN LA FOSFORILACIÓN DE RESIDUOS ESPECÍFICOS DE TIROSINA EN PROTEÍNAS POR LO QUE SON DE UTILIDAD EN TRASTORNOS O ENFERMEDADES PROLIFERATIVAS MALIGNAS RESULTANTES DE LA ACTIVACIÓN INAPROPIADA DEL SISTEMA INMUNE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98126507P | 2007-10-19 | 2007-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201000099A true GT201000099A (es) | 2012-03-26 |
Family
ID=40174735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201000099A GT201000099A (es) | 2007-10-19 | 2010-04-16 | Productos quimioterapéuticos cristalinos |
Country Status (19)
Country | Link |
---|---|
US (1) | US7772404B2 (es) |
EP (1) | EP2195299A1 (es) |
JP (1) | JP2011500708A (es) |
KR (1) | KR20100084665A (es) |
CN (1) | CN101827825B (es) |
AU (1) | AU2008312534A1 (es) |
BR (1) | BRPI0818337A2 (es) |
CA (1) | CA2699356A1 (es) |
CO (1) | CO6270221A2 (es) |
CR (1) | CR11444A (es) |
DO (1) | DOP2010000111A (es) |
EC (1) | ECSP10010175A (es) |
GT (1) | GT201000099A (es) |
MX (1) | MX2010004287A (es) |
PA (1) | PA8800401A1 (es) |
RU (1) | RU2010119920A (es) |
UA (1) | UA99490C2 (es) |
WO (1) | WO2009052231A1 (es) |
ZA (1) | ZA201002094B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
PL1638941T3 (pl) * | 2003-05-22 | 2010-11-30 | Abbvie Bahamas Ltd | Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz |
US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
WO2007015578A1 (ja) * | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
WO2007076358A1 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
CA2667720A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg. | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2008
- 2008-10-15 US US12/251,918 patent/US7772404B2/en not_active Expired - Fee Related
- 2008-10-16 CN CN2008801119519A patent/CN101827825B/zh not_active Expired - Fee Related
- 2008-10-16 BR BRPI0818337A patent/BRPI0818337A2/pt not_active IP Right Cessation
- 2008-10-16 MX MX2010004287A patent/MX2010004287A/es active IP Right Grant
- 2008-10-16 CA CA2699356A patent/CA2699356A1/en not_active Abandoned
- 2008-10-16 RU RU2010119920/04A patent/RU2010119920A/ru not_active Application Discontinuation
- 2008-10-16 JP JP2010530094A patent/JP2011500708A/ja active Pending
- 2008-10-16 UA UAA201006031A patent/UA99490C2/ru unknown
- 2008-10-16 KR KR1020107011003A patent/KR20100084665A/ko not_active Application Discontinuation
- 2008-10-16 EP EP08839994A patent/EP2195299A1/en not_active Withdrawn
- 2008-10-16 AU AU2008312534A patent/AU2008312534A1/en not_active Abandoned
- 2008-10-16 WO PCT/US2008/080068 patent/WO2009052231A1/en active Application Filing
- 2008-10-17 PA PA20088800401A patent/PA8800401A1/es unknown
-
2010
- 2010-03-24 ZA ZA2010/02094A patent/ZA201002094B/en unknown
- 2010-04-16 DO DO2010000111A patent/DOP2010000111A/es unknown
- 2010-04-16 GT GT201000099A patent/GT201000099A/es unknown
- 2010-04-27 CO CO10049269A patent/CO6270221A2/es not_active Application Discontinuation
- 2010-05-14 EC EC2010010175A patent/ECSP10010175A/es unknown
- 2010-05-19 CR CR11444A patent/CR11444A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CR11444A (es) | 2010-10-05 |
US20090124816A1 (en) | 2009-05-14 |
RU2010119920A (ru) | 2011-11-27 |
MX2010004287A (es) | 2010-04-30 |
WO2009052231A1 (en) | 2009-04-23 |
CN101827825A (zh) | 2010-09-08 |
EP2195299A1 (en) | 2010-06-16 |
CO6270221A2 (es) | 2011-04-20 |
AU2008312534A1 (en) | 2009-04-23 |
ECSP10010175A (es) | 2010-06-29 |
CN101827825B (zh) | 2012-11-21 |
DOP2010000111A (es) | 2010-07-15 |
JP2011500708A (ja) | 2011-01-06 |
PA8800401A1 (es) | 2009-05-15 |
BRPI0818337A2 (pt) | 2017-05-23 |
KR20100084665A (ko) | 2010-07-27 |
UA99490C2 (en) | 2012-08-27 |
US7772404B2 (en) | 2010-08-10 |
CA2699356A1 (en) | 2009-04-23 |
ZA201002094B (en) | 2011-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121572T1 (el) | Σκευασμα δισκιου του ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου για χρηση στη θεραπεια κυστικης ινωσης | |
NO20085243L (no) | Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting | |
CY1109084T1 (el) | Προϊον ζαχαροπλαστικης με χαμηλα λιπαρα | |
BR112014027244A2 (pt) | derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1 | |
EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
BR112014028841A2 (pt) | processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
BR122021002201A8 (pt) | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença | |
EA201270225A1 (ru) | СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА | |
CL2007002949A1 (es) | Forma cristalina del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; proceso para la preparacion de dicha forma cristalina; composicion fitoprotectora; | |
EA201270361A1 (ru) | Птеридины и их применение в качестве агрохимикатов | |
BR112018073951A2 (pt) | forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
GT201000099A (es) | Productos quimioterapéuticos cristalinos | |
AR065278A1 (es) | Sales de derivado de benzotiazol | |
GT201000101A (es) | Productos quimioterapéuticos cristalinos | |
EA201390351A1 (ru) | Спрей для носа | |
RS54639B1 (en) | PCSK9 VACCINE | |
MA32717B1 (fr) | Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide | |
ITCR20050007A1 (it) | Fondello di supporto per prodotti cosmetici | |
IL189286A0 (en) | Novel cysteine protease inhibitors and their therapeutic applications | |
ATE472316T1 (de) | Haarbehandlungszusammensetzungen | |
GT200600141A (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares | |
DOP2010000112A (es) | Productos quimioterapeuticos cristalinos | |
EA200702318A1 (ru) | Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса | |
GT201000093A (es) | Productos quimioterapéuticos cristalinos | |
MX2008007195A (es) | Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas. |